ArticleThe journal of allergy and clinical immunology. In practice2019
The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives.
Article in The journal of allergy and clinical immunology. In practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.Experimental hematology & oncology · 2026Article
- Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.Journal of hematology & oncology · 2026Article
- Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.British journal of haematology · 2025Article
- Next Generation Sequencing of Genes With Epigenetic Alterations in Mastocytosis.Clinical and translational allergy · 2025Article
- Article
- Prevalence and incidence of mastocytosis in adults: a Danish nationwide register study.European journal of epidemiology · 2025Article
- Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM.Blood advances · 2024Article
- The diagnostic workup for systemic mastocytosis differs from consensus recommendations: Results of a worldwide survey.The World Allergy Organization journal · 2023Article
- Genome-Wide DNA Methylation and Gene Expression in Patients with Indolent Systemic Mastocytosis.International journal of molecular sciences · 2023Article
- Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.Blood advances · 2023Article
- Acute mast cell leukemia without KIT D816V mutation and lack of CD2 and CD25-a case report of rare entity.Journal of hematopathology · 2023Article
- A Practical Approach to Systemic Mastocytosis Complications in Cardiac Surgery: A Case Report and Systematic Review of the Literature.Journal of clinical medicine · 2023Review
- Comprehensive mastocytosis data analysis from a single center.BMC cancer · 2023Article
- Article
- How persons with systemic mastocytosis describe the time between symptom onset and receiving diagnosis.Primary health care research & development · 2022Article
- Evaluation and Classification of Mast Cell Disorders: A Difficult to Manage Pathology in Clinical Practice.Cureus · 2022Review
- Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis.Leukemia · 2022Article
- Systemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase.Case reports in hematology · 2022Article
- Case report of a clinically indolent but morphologically high-grade cutaneous mast cell tumor in an adult: Atypical cutaneous mastocytoma or mast cell sarcoma?Journal of cutaneous pathology · 2021Article
- DNA methylation profile in patients with indolent systemic mastocytosis.Clinical and translational allergy · 2021Article
Corrections and comments
- Commented on by
Authors and funding
49 authors.
Funding
Abstract
Mastocytosis is a unique hematologic neoplasm with complex biology and pathology and a variable clinical course. The disease can essentially be divided into cutaneous mastocytosis (CM) and systemic mastocytosis (SM). In adults, SM is diagnosed in most cases and manifests as either indolent or advanced disease. Patients with advanced SM have an unfavorable prognosis with reduced survival. However, so far, little is known about the prevalence of various categories of SM and about prognostic factors. In an attempt to learn more about the behavior and evolution of various forms of CM and SM, the European Competence Network on Mastocytosis (ECNM) initiated a mastocytosis registry in 2012. In this article, the set up and start phase of this registry are described. Until 2018, more than 3000 patients from 12 countries and 25 centers have been enrolled. In a majority of all patients, robust follow-up data and relevant clinical end points are available. Using this data set, a series of registry projects have been launched, with the aim to validate previously identified diagnostic and prognostic variables and to identify new disease-related and patient-related parameters in various forms of mastocytosis. Moreover, the core data set of the registry will be useful to establish multiparametric scoring systems through which prognostication and individualized management of patients with mastocytosis should improve in the foreseeable future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.